{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T02:05:14Z","timestamp":1780538714872,"version":"3.54.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The optimal first-line therapy for metastatic renal cell carcinoma (mRCC) remains uncertain, despite recent advancements in immune-based combinations. This retrospective study compares the effectiveness of pembrolizumab plus axitinib (PA) and nivolumab plus cabozantinib (NC) as first-line treatments for mRCC in a real-world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patient data were collected from 55 centers across 16 countries, encompassing individuals diagnosed with mRCC receiving first-line treatment with PA or NC between January 2016 and October 2023. Clinical and tumor features and treatment responses were recorded. The primary endpoints were overall response rate (ORR), overall survival (OS), progression-free survival (PFS), and time to second progression. Statistical analyses included Kaplan\u2013Meier survival estimates, Cox proportional hazard models, and chi-square tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 760 patients with a median age of 64\u00a0years (range, 29\u201388) were included. Of them, 607 received PA, and only 153 NC. In the overall study population, ORR was 59% for and 49% for PA. Median OS was 55.7\u00a0months and not reached (NR) for PA and NC, respectively (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.51), while median PFS was longer with NC (27.6\u00a0months) than for PA (16.2\u00a0months,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.003). Subgroup analysis suggested a PFS benefits for NC in male, younger patients, intermediate risk group, clear cell histology, and lung involvement, as well as ORR favored NC in good risk patients. Multivariate analysis identified first-line therapy as a significant factor associated with PFS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this certainly biased retrospective comparison, NC demonstrated superior ORR and longer PFS compared to PA in mRCC. These findings underscore the importance of considering individual patient characteristics and risk profiles when selecting first-line therapy for mRCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00262-025-04043-x","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T08:03:40Z","timestamp":1748333020000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)"],"prefix":"10.1007","volume":"74","author":[{"given":"Matteo","family":"Santoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giandomenico","family":"Roviello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Grande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ondrej","family":"Fiala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Seront","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Molina-Cerrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Pichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zin W.","family":"Myint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Kucharz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindran","family":"Kanesvaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"B\u00fcttner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Pichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Basso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jindrich","family":"Kopecky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria T.","family":"Bourlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Cerbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Buchler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso G\u00f3mez","family":"de Lia\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Gianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Zgura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Rescigno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawaher","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orazio","family":"Caffo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zs\u00f3fia","family":"K\u00fcronya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giuseppa","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipen","family":"Bhuva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Catalano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuno","family":"Vau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray Manneh","family":"Kopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Buti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aristotelis","family":"Bamias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillo","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaisa","family":"Sunela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Massari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"4043_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/CAAC.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/CAAC.21660","journal-title":"CA Cancer J Clin"},{"key":"4043_CR2","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1097\/00000478-200305000-00005","volume":"27","author":"JC Cheville","year":"2003","unstructured":"Cheville JC, Lohse CM, Zincke H et al (2003) Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 27:612\u2013624. https:\/\/doi.org\/10.1097\/00000478-200305000-00005","journal-title":"Am J Surg Pathol"},{"key":"4043_CR3","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s00345-016-1773-y","volume":"34","author":"S Dabestani","year":"2016","unstructured":"Dabestani S, Thorstenson A, Lindblad P et al (2016) Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study. World J Urol 34:1081\u20131086. https:\/\/doi.org\/10.1007\/s00345-016-1773-y","journal-title":"World J Urol"},{"key":"4043_CR4","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1200\/jco.2002.20.1.289","volume":"20","author":"RJ Motzer","year":"2002","unstructured":"Motzer RJ, Bacik J, Murphy BA et al (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289\u2013296. https:\/\/doi.org\/10.1200\/jco.2002.20.1.289","journal-title":"J Clin Oncol"},{"key":"4043_CR5","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","volume":"27","author":"DYC Heng","year":"2009","unstructured":"Heng DYC, Xie W, Regan MM et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27:5794\u20135799. https:\/\/doi.org\/10.1200\/JCO.2008.21.4809","journal-title":"J Clin Oncol"},{"key":"4043_CR6","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/nejmoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V et al (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380:1116\u20131127. https:\/\/doi.org\/10.1056\/nejmoa1816714","journal-title":"N Engl J Med"},{"key":"4043_CR7","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/nejmoa2026982","volume":"384","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Powles T, Burotto M et al (2021) Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 384:829\u2013841. https:\/\/doi.org\/10.1056\/nejmoa2026982","journal-title":"N Engl J Med"},{"key":"4043_CR8","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/nejmoa2035716","volume":"384","author":"R Motzer","year":"2021","unstructured":"Motzer R, Alekseev B, Rha S-Y et al (2021) Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 384:1289\u20131300. https:\/\/doi.org\/10.1056\/nejmoa2035716","journal-title":"N Engl J Med"},{"key":"4043_CR9","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/nejmoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, Penkov K, Haanen J et al (2019) Avelumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma. N Engl J Med 380:1103\u20131115. https:\/\/doi.org\/10.1056\/nejmoa1816047","journal-title":"N Engl J Med"},{"key":"4043_CR10","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/nejmoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF et al (2018) Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma. N Engl J Med 378:1277\u20131290. https:\/\/doi.org\/10.1056\/nejmoa1712126","journal-title":"N Engl J Med"},{"key":"4043_CR11","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/J.EUROS.2022.12.015","volume":"49","author":"NJ Shah","year":"2023","unstructured":"Shah NJ, Sura SD, Shinde R et al (2023) Real-world treatment patterns and clinical outcomes for metastatic renal cell carcinoma in the current treatment era. Eur Urol Open Sci 49:110. https:\/\/doi.org\/10.1016\/J.EUROS.2022.12.015","journal-title":"Eur Urol Open Sci"},{"key":"4043_CR12","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s11523-023-00978-2","volume":"18","author":"M Santoni","year":"2023","unstructured":"Santoni M, Massari F, Myint ZW et al (2023) Global real-world outcomes of patients receiving immuno-oncology combinations for advanced renal cell carcinoma: the ARON-1 study. Target Oncol 18:559\u2013570. https:\/\/doi.org\/10.1007\/s11523-023-00978-2","journal-title":"Target Oncol"},{"key":"4043_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2023.03.006","author":"M Santoni","year":"2023","unstructured":"Santoni M, Massari F, Myint ZW et al (2023) Clinico-pathological features influencing the prognostic role of body mass index in patients with advanced renal cell carcinoma treated by immuno-oncology combinations (ARON-1). Clin Genitourin Cancer. https:\/\/doi.org\/10.1016\/j.clgc.2023.03.006","journal-title":"Clin Genitourin Cancer"},{"key":"4043_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2023.07.003","author":"M Santoni","year":"2023","unstructured":"Santoni M, Buti S, Myint ZW et al (2023) Real-world outcome of patients with advanced renal cell carcinoma and intermediate- or poor-risk international metastatic renal cell carcinoma database consortium criteria treated by immune-oncology combinations: differential effectiveness by risk group? Eur Urol Oncol. https:\/\/doi.org\/10.1016\/j.euo.2023.07.003","journal-title":"Eur Urol Oncol"},{"key":"4043_CR15","doi-asserted-by":"publisher","first-page":"460","DOI":"10.23736\/S2724-6051.23.05369-7","volume":"75","author":"C Porta","year":"2023","unstructured":"Porta C, Bamias A, Zakopoulou R et al (2023) Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations. Minerva Urol Nephrol 75:460\u2013470","journal-title":"Minerva Urol Nephrol"},{"key":"4043_CR16","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Liti\u00e8re S, De Vries E et al (2016) RECIST 1.1\u2014update and clarification: from the RECIST committee. Eur J Cancer 62:132\u2013137. https:\/\/doi.org\/10.1016\/j.ejca.2016.03.081","journal-title":"Eur J Cancer"},{"key":"4043_CR17","doi-asserted-by":"publisher","unstructured":"(2019) FDA approves pembrolizumab plus axitinib for advanced renal cell carcinoma. Case Med Res. https:\/\/doi.org\/10.31525\/fda1-ucm636395.htm","DOI":"10.31525\/fda1-ucm636395.htm"},{"issue":"17_suppl","key":"4043_CR18","doi-asserted-by":"publisher","first-page":"LBA4501","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4501","volume":"41","author":"BI Rini","year":"2023","unstructured":"Rini BI, Plimack ER, Stus V et al (2023) Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426. J Clin Oncol 41(17_suppl):LBA4501\u2013LBA4501. https:\/\/doi.org\/10.1200\/JCO.2023.41.17_suppl.LBA4501","journal-title":"J Clin Oncol"},{"key":"4043_CR19","unstructured":"FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma\u2014The ASCO Post. https:\/\/ascopost.com\/issues\/february-10-2021\/fda-approves-nivolumab-plus-cabozantinib-for-advanced-renal-cell-carcinoma\/. Accessed 27 Oct 2023"},{"key":"4043_CR20","doi-asserted-by":"publisher","first-page":"S1159","DOI":"10.1016\/j.annonc.2020.08.2257","volume":"31","author":"TK Choueiri","year":"2020","unstructured":"Choueiri TK, Powles T, Burotto M et al (2020) 696O_PR Nivolumab\u2009+\u2009cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: first results from the randomized phase III CheckMate 9ER trial. Ann Oncol 31:S1159. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.2257","journal-title":"Ann Oncol"},{"key":"4043_CR21","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1200\/JCO.2023.41.6_suppl.603","volume":"41","author":"M Burotto","year":"2023","unstructured":"Burotto M, Powles T, Escudier B et al (2023) Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial. J Clin Oncol 41:603\u2013603. https:\/\/doi.org\/10.1200\/JCO.2023.41.6_suppl.603","journal-title":"J Clin Oncol"},{"key":"4043_CR22","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.euo.2021.03.001","volume":"4","author":"F Quhal","year":"2021","unstructured":"Quhal F, Mori K, Bruchbacher A et al (2021) First-line immunotherapy-based combinations for metastatic renal cell carcinoma: a systematic review and network meta-analysis. Eur Urol Oncol 4:755\u2013765. https:\/\/doi.org\/10.1016\/j.euo.2021.03.001","journal-title":"Eur Urol Oncol"},{"key":"4043_CR23","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.eururo.2021.03.016","volume":"80","author":"RI Bin","year":"2021","unstructured":"Bin RI, He H, Ryu AJ et al (2021) A living, interactive systematic review and network meta-analysis of first-line treatment of metastatic renal cell carcinoma [formula presented]. Eur Urol 80:712\u2013723","journal-title":"Eur Urol"},{"key":"4043_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102377","volume":"106","author":"P Lombardi","year":"2022","unstructured":"Lombardi P, Filetti M, Falcone R et al (2022) New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: a systematic review and network meta-analysis. Cancer Treat Rev 106:102377. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102377","journal-title":"Cancer Treat Rev"},{"key":"4043_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/J.PHARMTHERA.2023.108499","author":"M Catalano","year":"2023","unstructured":"Catalano M, Procopio G, Sepe P et al (2023) Tyrosine kinase and immune checkpoints inhibitors in favorable risk metastatic renal cell carcinoma: Trick or treat? Pharmacol Ther. https:\/\/doi.org\/10.1016\/J.PHARMTHERA.2023.108499","journal-title":"Pharmacol Ther"},{"key":"4043_CR26","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s00345-023-04412-0","volume":"41","author":"T Yanagisawa","year":"2023","unstructured":"Yanagisawa T, Kawada T, Quhal F et al (2023) Impact of sex on the efficacy of immune checkpoint inhibitors in kidney and urothelial cancers: a systematic review and meta-analysis. World J Urol 41:1763\u20131774. https:\/\/doi.org\/10.1007\/s00345-023-04412-0","journal-title":"World J Urol"},{"key":"4043_CR27","doi-asserted-by":"publisher","first-page":"64.e17","DOI":"10.1016\/j.urolonc.2021.09.009","volume":"40","author":"R Satkunasivam","year":"2022","unstructured":"Satkunasivam R, Guzman JC, Klaassen Z et al (2022) Association between prior nephrectomy and efficacy of immune checkpoint inhibitor therapy in metastatic renal cell carcinoma\u2014a systematic review and meta-analysis. Urol Oncol Semin Orig Investig 40:64.e17-64.e24. https:\/\/doi.org\/10.1016\/j.urolonc.2021.09.009","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"4043_CR28","doi-asserted-by":"publisher","DOI":"10.2217\/IMT-2023-0039","author":"T Yanagisawa","year":"2023","unstructured":"Yanagisawa T, Quhal F, Kawada T et al (2023) Association between age and efficacy of first-line immunotherapy-based combination therapies for mRCC: a meta-analysis. Immunotherapy. https:\/\/doi.org\/10.2217\/IMT-2023-0039","journal-title":"Immunotherapy"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04043-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04043-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04043-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:59:37Z","timestamp":1757555977000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04043-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":28,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["4043"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04043-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4125332\/v1","asserted-by":"object"}]},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"assertion":[{"value":"18 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been updated to amend the license information","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Marche (CERM) n. 1164\/2020 and written informed consent was obtained from all participating patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"225"}}